Chuanhai Cao

This inventor holds 17 USPTO granted patents and 6 published patent applications and 2 EPO patents, primarily in Neurodegenerative Diseases. Top assignees: University of South Florida, Meganano Biotech, Inc., Rhodes Technologies. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chuanhai Cao. Retrieved from https://idiyas.com/inventor/chuanhai-cao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 6)

% Patents Active = 82.4

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 1.9

ph-index = 3

Forward Citations = 20(Granted Patents)

Location History:

Temple Terrace, FL (US) (2013 - 2018)
Tampa, FL (US) (2011 - 2022)

Company Filing History:

17 out of 1,993

University of South Florida

patents

1 out of 1

Meganano Biotech, Inc.

The United States Government as Represented by the Department of Veterans Affairs

patents

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Cannabinoid Compositions

Alzheimer's Disease

Protein Aggregation

Neurodegenerative Diseases

Dendritic Cells

Sulfono-Gamma-AA Peptides

Parkinson's Disease

Electromagnetic Field Treatment

Amyloid Beta Peptides

Therapeutic Agents

Vaccines

TCR Clonality

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12702690 - Cannabinoid compositions and dosage forms for intranasal or inhalational delivery (2026-08-11),

2. 12329807 - Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases (2025-06-17),

3. 12145969 - Compositions and methods relating to novel sulfono-gamma-AA peptides (2024-11-19),

4. 11446276 - Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer's disease (2022-09-20),

5. 11254704 - Compounds and methods for reducing or inhibiting aggregation of proteins in a subject (2022-02-22),

6. 11065225 - Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease (2021-07-20),

7. 10836793 - Compounds for the treatment of neurodegenerative diseases (2020-11-17),

8. 10653759 - Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of Parkinson's disease (2020-05-19),

9. 10538553 - Compounds for the treatment of neurodegenerative diseases (2020-01-21),

10. 10155030 - Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinsons disease (2018-12-18),

11. 10149982 - Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment (2018-12-11),

12. 10022420 - [object Object] (2018-07-17),

13. 9645155 - [object Object] (2017-05-09),

14. 9238149 - Prevention and treatment of alzheimer'S disease through electromagnetic field exposure (2016-01-19),

15. 8383347 - Method of diagnosing or assessing risk for Parkinson's disease or Alzheimer's disease using TCR clonality (2013-02-26),

Title: Chuanhai Cao: Innovator in Immunotherapy and Neuroprotection

Introduction

Chuanhai Cao is a prominent inventor based in Tampa, FL (US), known for his significant contributions to the fields of immunotherapy and neuroprotection. With a total of 17 patents, he has made remarkable strides in developing innovative therapeutic approaches to combat various diseases.

Latest Patents

Cao's latest patents include groundbreaking work on "Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases." This patent discloses exogenous antigen sensitized immature dendritic cells, which may be utilized to elicit an increased immune response. Additionally, he has developed vaccines comprising these dendritic cells, along with methods for inducing an immune response in patients and treating diseases. Another notable patent is focused on "Compositions and methods relating to novel sulfono-gamma-AA peptides." This work presents compounds and pharmaceutical compositions that exhibit minimal toxicity, repair neuronal damage, inhibit Amyloid beta aggregation, and promote cellular growth and viability.

Career Highlights

Cao has worked with esteemed institutions such as the University of South Florida and the United States Government as represented by the Department of Veterans Affairs. His research has significantly impacted the understanding and treatment of immune-related diseases and neurodegenerative conditions.

Collaborations

Cao has collaborated with notable colleagues, including Jianfeng Cai and Xiaoyang Lin, contributing to the advancement of research in his field.

Conclusion

Chuanhai Cao's innovative work and numerous patents highlight his dedication to improving therapeutic strategies for diseases. His contributions continue to influence the fields of immunotherapy and neuroprotection, showcasing the importance of research and innovation in healthcare.

Profile summary based on public USPTO records.